⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRD News
Opus Genetics, Inc. Common Stock
Form 8-K
sec.gov
IRD
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
globenewswire.com
IRD
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
globenewswire.com
LGVN
IRD
DERM
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IRD
Form 8-K
sec.gov
IRD
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
globenewswire.com
IRD
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
globenewswire.com
IRD
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
globenewswire.com
IRD
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
globenewswire.com
IRD
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
globenewswire.com
IRD